作者
Radha Rajasingham, Ananta S Bangdiwala, Melanie R Nicol, Caleb P Skipper, Katelyn A Pastick, Margaret L Axelrod, Matthew F Pullen, Alanna A Nascene, Darlisha A Williams, Nicole W Engen, Elizabeth C Okafor, Brian I Rini, Ingrid A Mayer, Emily G McDonald, Todd C Lee, Peter Li, Lauren J MacKenzie, Justin M Balko, Stephen J Dunlop, Katherine H Hullsiek, David R Boulware, Sarah M Lofgren, COVID PREP team Abassi Mahsa Balster Andrew Collins Lindsey B Drobot Glen Krakower Douglas S Lother Sylvain A MacKay Dylan S Meyer-Mueller Cameron Selinsky Stephen Solvason Dayna Zarychanski Ryan Zash Rebecca
发表日期
2021/6/1
期刊
Clinical Infectious Diseases
卷号
72
期号
11
页码范围
e835-e843
出版商
Oxford University Press
简介
Background
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging virus causing the ongoing coronavirus disease 2019 (COVID-19) pandemic with no known effective prophylaxis. We investigated whether hydroxychloroquine could prevent SARS-CoV-2 in healthcare workers at high risk of exposure.
Methods
We conducted a randomized, double-blind, placebo-controlled clinical trial of healthcare workers with ongoing exposure to persons with SARS-CoV-2, including those working in emergency departments, intensive care units, COVID-19 hospital wards, and first responders. Participants across the United States and in the Canadian province of Manitoba were randomized to hydroxychloroquine loading dose then 400 mg once or twice weekly for 12 weeks. The primary endpoint was confirmed or probable COVID-19–compatible illness. We …
学术搜索中的文章
R Rajasingham, AS Bangdiwala, MR Nicol, CP Skipper… - Clinical Infectious Diseases, 2021